Coronavirus outbreak clouds AstraZeneca's Q4 results and 2020 outlook
LONDON — With nearly a fifth of total sales coming from China, AstraZeneca counts the coronavirus-hit nation as one of its biggest growth drivers. The impact of the deadly epidemic has unsurprisingly weighed on the British drugmaker’s fourth-quarter results.
On Friday, AstraZeneca posted fourth-quarter sales of $6.25 billion, just shy of Wall Street estimates. Nearly $1.2 billion of that product revenue came from China.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 86,600+ biopharma pros reading Endpoints daily — and it's free.